Stopping Ozempic to Get Pregnant With PCOS (Now PMOS): The Two-Month Rule and What Happens in the Gap

For a lot of women, this is the first genuinely confusing decision the medication creates.

You started a GLP-1 for weight, or for insulin resistance, or because your cycles had gone quiet. Some months in, the cycles came back. And now the thing you actually want — to try for a baby — requires you to stop the drug that appears to have made trying possible.

That's not a small ask, and most of what's written about it isn't written for you. Search this and you'll find page after page about "Ozempic babies" and whether the medication is safe in pregnancy. Almost none of it answers the question women with PCOS — now PMOS, after the 2026 Lancet consensus renamed it — are actually asking: what happens in the window between stopping and conceiving?

Here's what's on the label, what the 2026 evidence supports, and what is honestly still unknown.

The two-month wait is on the label, not internet advice

This one gets repeated so often on telehealth blogs that it starts to sound like folklore. It isn't.

The FDA prescribing information for Ozempic, in the pregnancy section, says it plainly: discontinue semaglutide in women at least two months before a planned pregnancy, because of the long washout period for the drug. The same section notes animal reproduction studies showing embryofetal harm, and says use in pregnancy is only justified if the potential benefit outweighs the potential risk to the fetus.

Two things follow. First, the interval is tied to how long semaglutide specifically takes to clear — it is not a universal number you can apply to whichever GLP-1 you happen to be on. Different molecules have different half-lives, and the interval for yours is a prescriber question. Second, because that guidance exists, this is the one reason for stopping that has a defined timeline attached to it. Cost, side effects, and plateaus don't.

The part nobody writes about: you have to stop right when you need the cycles

Here is the sequencing problem, stated bluntly.

If your ovulation improved on the medication, then a chunk of your fertility is currently borrowed from a drug you're required to put down two months before you start trying. The washout lands in the exact window where regular cycles matter most. And that window is also when weight regain typically begins.

We looked for a page that addresses this directly. Fertility clinics cover pregnancy safety. Telehealth operators cover starting. Nobody sequences the middle. That's not because the problem is rare — it's because the answer is uncomfortable: there is no trial that has followed women with PMOS off a GLP-1 and into conception attempts. What exists is adjacent evidence, and it's worth knowing precisely what it does and doesn't cover.

What's actually known about GLP-1s and ovulation

Until recently, "GLP-1s restore ovulation in PCOS" was asserted everywhere and sourced nowhere. As of July 2026, there's a number.

A study published in Journal of Clinical Medicine (Carmina and Longo, 2026) followed 96 women with PMOS and a BMI above 25 through six months of semaglutide. Among those who had been anovulatory, 52.5% resumed ovulatory cycles. Average weight loss was 11.3%. The response split sharply by starting weight: around 95% of the overweight group regained ovulatory cycles, versus roughly 25% of those with moderate to severe obesity.

That is the best-sourced version of this claim available, and it still comes with real limits. Single center. No control group. Which means it cannot separate the drug from the weight loss — and weight loss on its own is known to restore ovulation in PMOS. So the honest framing is that ovulation was associated with treatment, not proven to depend on the molecule.

Why that distinction matters for you: if the ovulation came from the weight change rather than from semaglutide itself, then holding the weight through the washout matters more than the drug being in your system on any given week.

A second, much smaller study gets cited constantly as a fertility result. A 2026 pilot in Clinical Nutrition ESPEN followed 20 women with PCOS, obesity, and prediabetes on metformin plus low-dose semaglutide for six months; 60% conceived. Encouraging — and also 20 people, single-arm, no comparison group, with the pregnancies occurring inside the treatment period rather than after a documented washout. It's a signal about the metabolic setup, not a protocol.

What comes back in the gap — and what's being studied to blunt it

Weight regain after stopping is well documented and not a discipline problem. The newest pooled figure is the useful one here.

A 2026 systematic review and meta-analysis in Cureus pulled 17 studies covering 3,793 people and found post-cessation regain averaging 7.20% of body weight — but the average hides the decision-relevant part. By drug: tirzepatide 13.04%, semaglutide 7.19%, liraglutide 4.83%. Across the three randomized trials that compared them directly, stopping arms ended up 14.26 percentage points heavier than continuation arms.

So "how much will I regain during the washout" has a different answer depending on which molecule you're taking, and that difference is large enough to plan around. It's a question your prescriber can answer specifically for your regimen — and it's the sort of thing worth raising before you set a date, not after.

For PMOS specifically, the follow-on question is whether cycles track the weight back up. There's no clean answer, and we're not going to invent one. What's reasonable to say: if your cycles improved as the weight came down, treat the possibility that they drift again as something to monitor rather than assume away.

One approach does show up in the PMOS literature for the gap itself: keeping metformin on board through and after semaglutide withdrawal. A two-year observational study (Jensterle and colleagues, 2024) followed women with obesity and PCOS who stayed on metformin after stopping semaglutide, and weight remained meaningfully below baseline at two years. That's a real finding — and it's observational with no control arm, so it cannot show that metformin caused the weight to hold. It fits the situation, since metformin is familiar territory in PMOS care and sits on the same insulin pathway. Whether it belongs in your washout is a conversation for the clinician managing your care.

The other thing people improvise — stepping the dose down instead of stopping outright — doesn't apply here. The label instruction is to discontinue, not to reduce.

The first real guideline landed, and it's mostly honest about the blanks

In late July 2026, an international group published the first systematic scoping review and consensus guidance on incretin-based medications across the whole reproductive span — contraception, preconception, pregnancy, lactation — in Obesity Reviews.

The most useful thing in it is what it admits. Across 34 studies, the group found sufficient evidence to answer only 56.3% of its own research questions. No study reported an increase in congenital anomalies. That's reassuring as far as it goes, and it is explicitly not the same as a clean safety record established in humans.

Two practical points come out of it. Contraception during treatment is part of the conversation, not an afterthought — improved ovulation means the possibility of conceiving sooner than planned, which is the entire origin of the "Ozempic babies" stories. And if you find out you're pregnant while still on a GLP-1, that is a same-week call to your prescriber, not a reason to panic quietly.

How to sequence the conversation

Bring the date. "I want to start trying" changes the plan in ways that cost or side effects don't, and it's the one reason for stopping that has an interval attached.

Ask which molecule and which interval. The two-month figure belongs to semaglutide's washout. Yours may differ.

Ask what carries the metabolic work during the gap. That's the real question underneath this whole article, and it has no default answer.

Get baseline cycle data first. A few months of tracked cycles before you stop tells you far more than a memory will, and it's the only way to notice drift early.

And it helps to know which version of PMOS you're working with before you plan around it. Insulin-driven presentations are the ones GLP-1s act on most directly; androgen-dominant and ovulation-driven presentations don't behave the same way on the way down or the way back up. Our free assessment reads your symptom pattern and points to the driver most likely behind yours in about five minutes — no labs, and it won't diagnose you, but it tells you which markers are worth watching through the washout. Our read of the 2026 GLP-1 evidence has the full-dose picture for context.

---

We inform; we don't diagnose or prescribe. Semaglutide and other GLP-1 medications are prescription drugs, and they're used off-label for PMOS in most places. When and how to stop one — especially around pregnancy — is a decision for you and your clinician, not an article.

Sources

• Ozempic (semaglutide) injection — FDA Prescribing Information, Section 8.1 (Pregnancy), revised May 2026. Novo Nordisk. States that Ozempic should be discontinued in women at least 2 months before a planned pregnancy due to semaglutide's long washout period.
• Carmina E, Longo RA. Evidence That Semaglutide Represents an Important Tool for Treatment of Irregular Menses and Chronic Anovulation in Women with Polyendocrine Metabolic Ovarian Syndrome. Journal of Clinical Medicine, 2026 Jul 2. PMID: 42452625
• Maslin K, Shawe J, Blowers S, et al. Incretin-Based Medications in Women and Reproduction: A Systematic Scoping Review and Consensus Guidelines for Clinical Practice. Obesity Reviews, 2026 Jul 29. PMID: 42528099
• Patel H, Babli SA, Shah S, et al. Post-cessation Weight Regain After Weight Management Medications: A Systematic Review and Meta-Analysis. Cureus, 2026 Jun. PMID: 42534203
• Jensterle M, Ferjan S, Janez A. The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study. Frontiers in Endocrinology, 2024. PMID: 38665260
• Bolek T, Turňová P, Janošova S, et al. Effect of semaglutide with metformin for weight loss and fertility in polycystic ovary syndrome (PCOS) patients with obesity: A pilot prospective study. Clinical Nutrition ESPEN, 2026 Feb;71:102885. PMID: 41421448
• Teede HJ, et al. 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Monash University / international consensus, 2023.